Neelum Shahzadi

Inflammatory Bowel Disease (IBD), which includes Crohn’s Disease (CD) and Ulcerative Colitis (UC), is a long-term condition caused by abnormal immune responses that lead to ongoing inflammation in the gut. Its roots are complex, involving a mix of genetics, environmental triggers, gut bacteria, and immune system issues. In recent years, the way we treat IBD has changed dramatically. We’ve moved beyond just managing symptoms with anti-inflammatory and immunosuppressive drugs. Now, we use biologic therapies—advanced treatments made from living cells that target specific parts of the immune system responsible for inflammation. A major breakthrough came with TNF-α inhibitors like infliximab and adalimumab. These drugs help many patients achieve remission, heal their intestinal lining, and feel significantly better overall. For those who don’t respond to these first-line options, newer treatments like vedolizumab (which targets integrins) and ustekinumab (which blocks interleukins IL-12 and IL-23) offer promising alternatives. Still, not everything is perfect. Some patients don’t respond to treatment right away, and others may stop responding over time, often due to their immune systems producing antibodies against the medication. When that happens, doctors might adjust the dose, switch to a different drug, or combine treatments to improve results. While many biologics affect the whole immune system, gut-specific drugs like vedolizumab offer a safer option for long-term use. Cost is another challenge, but biosimilars affordable versions of biologic drugs are making these treatments more accessible, especially in countries with limited healthcare resources. Even so, outcomes can differ from person to person based on how severe their disease is and how well they stick to their treatment plan. Looking ahead, the future of IBD treatment is all about personalized medicine. Scientists are working on finding biomarkers that can help predict which treatment will work best for each individual. New drugs, including small molecule therapies and more targeted biologics, are also on the horizon. Combining therapies may even become a strategy to improve results while minimizing side effects. In short, biologics have transformed the way we manage IBD, offering better disease control and improved quality of life. But research and innovation remain key to helping more people achieve lasting remission with fewer complications.

CRISPR stands for “Clustered Regularly Interspaced Short Palindromic Repeats”, which form the foundation of an ancient immune system in single-cell organisms, especially bacteria and archaea. It has shown a positive therapeutic potential by modifying the genetic mutations responsible for incurable genetic disorders. CRISPR has several benefits over other gene-editing tools, as it is convenient, inexpensive and efficient. Despite therapeutic potential, CRISPR can also help to make animal models to study disease development and progression, and also to study the effect of new drugs. CRISPR can help to treat several genetic diseases, including cancers, allergic diseases, immunological disorders, cardiovascular diseases, viral infections, cystic fibrosis, muscular dystrophy, Huntington’s disease, metabolic disorders, blood disorders and eye-related disorders. CRISPR can also help to treat celiac disease by modifying the gliadin content in the wheat crop. Pharmaceutical and therapeutic companies are developing CRISPR therapies against genetic diseases and are concerned about the off- target effects of CRISPR, along with its ethical, legal and safety concerns. CRISPR laws are more stringent in the European Union than in the United States, which critics believe could hamper the investment in this research. The future holds great promise for CRISPR in treating diseases, developing medicines and fostering agricultural production.